Clinical Trials Sponsored by Ionis Pharmaceuticals, Inc.

Total 4947 results

Ionis Pharmaceuticals, Inc.

Recruiting

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Cardiovascular Diseases | Atherosclerosis | Hypertriglyceridemia

United States, Spain, Netherlands, Canada, Poland, Denmark, Italy, Hungary, France, Portugal, Norway, Bulgaria, Czechia, Slovakia
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Puerto Rico, Belgium, Bulgaria, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Turkey, United Kingdom
Ionis Pharmaceuticals, Inc.

Recruiting

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

United States, Germany, Israel, Spain, Netherlands, Australia, Hungary, Sweden, Denmark, Canada, France, Italy, Turkey, Finland, Bulgaria, Czechia, New Zealand, Norway, Poland, Portugal, Slovakia, South Africa, United Kingdom
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

United States, Italy, Portugal, Spain, Taiwan, Sweden, Canada, Brazil, France, New Zealand, Argentina, Cyprus, Australia, Turkey
Ionis Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) (HORIZON)

Multiple System Atrophy

Austria, Portugal, France, Germany, United Kingdom
Ionis Pharmaceuticals, Inc.

Available

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome
Ionis Pharmaceuticals, Inc.

Completed

NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

United States, Spain, Taiwan, Italy, Germany, Argentina, Australia, Brazil, Canada, Cyprus, France, Greece, New Zealand, Portugal, Sweden, Turkey
Ionis Pharmaceuticals, Inc.

Active, not recruiting

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

United States, Australia, Spain, Canada, Germany, Japan, Italy, Israel, Argentina, France, Portugal, Austria, Brazil, Greece, United Kingdom, Czechia, Sweden, Belgium, Denmark, Poland, Puerto Rico
Ionis Pharmaceuticals, Inc.

Completed

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, France, Netherlands, Spain, United Kingdom, Belgium, Bulgaria, Canada, Denmark, Germany, Israel, Italy, Poland, Turkey
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome

Spain, United Kingdom, France, Canada, United States, Italy, Netherlands, Norway, Portugal, Slovakia, Sweden
Ionis Pharmaceuticals, Inc.

Active, not recruiting

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy

United States, Spain, Australia, Austria, Canada, Czechia, Netherlands, New Zealand, Poland
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly

Acromegaly

United States, Hungary, Serbia, Estonia, Italy, Latvia, Lithuania, Poland, Romania, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure (ASTRAAS)

Hypertension

United States, Canada
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

Hypertension

United States
Ionis Pharmaceuticals, Inc.

Completed

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

Crohn's Disease

United States, Canada
Ionis Pharmaceuticals, Inc.

Terminated

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

Type 2 Diabetes Mellitus

United States
Ionis Pharmaceuticals, Inc.

Completed

Natural History and Functional Status Study of Patients With Lafora Disease

Lafora Disease

United States, Italy, Spain
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547

Healthy Volunteers

Canada
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

Healthy Participants

United States
Ionis Pharmaceuticals, Inc.

Terminated

Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

Type 2 Diabetes

United States
Ionis Pharmaceuticals, Inc.

Completed

A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis

Cystic Fibrosis | Healthy Subjects

United Kingdom, Germany
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes

Hepatic Steatosis

Canada, Hungary, Poland, United Kingdom
Ionis Pharmaceuticals, Inc.

Withdrawn

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Geographic Atrophy | Age Related Macular Degeneration

Australia, United States, New Zealand
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Huntington's Disease

Canada, United Kingdom, Germany
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers

Thalassemia

Australia
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC)

Non-small Cell Lung Cancer

United States, Hungary, Poland, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Type 2 Diabetes Mellitus

Netherlands
Ionis Pharmaceuticals, Inc.

Completed

Safety Study of ISIS 325568 in Healthy Volunteers

Type 2 Diabetes Mellitus

Netherlands
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate the Safety and Efficacy of ION373 in Patients With Alexander Disease (AxD)

Alexander Disease

United States, United Kingdom, Australia, Canada, Israel, Italy, Japan, Netherlands
Ionis Pharmaceuticals, Inc.

Active, not recruiting

PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717.

Prion Disease

Spain, United States, Israel, Germany, Japan, Canada
Ionis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Hereditary Angioedema

Netherlands, United States
Ionis Pharmaceuticals, Inc.

Completed

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Castrate-Resistant Prostate Cancer

United States, Puerto Rico, Hungary, Romania, Russian Federation, Poland
Ionis Pharmaceuticals, Inc.

Completed

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

Healthy Participants

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Mild Alzheimer's Disease

United Kingdom, Netherlands, Germany, Sweden, Canada, Finland
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure

Mild Hypertension

United States
Ionis Pharmaceuticals, Inc.

Terminated

A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)

Chronic Obstructive Pulmonary Disease | Chronic Bronchitis

Germany, Czechia, Hungary, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

Hepatitis C, Chronic

United States
Ionis Pharmaceuticals, Inc.

Completed

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

Ulcerative Colitis

United States
Ionis Pharmaceuticals, Inc.

Completed

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

Ulcerative Colitis

United States
Ionis Pharmaceuticals, Inc.

Completed

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada
Ionis Pharmaceuticals, Inc.

Completed

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

Crohn's Disease

Poland, Spain, Belgium, Germany, Czechia, Italy
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904

Healthy Volunteers

Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers

Healthy Volunteers

Canada
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers

Healthy Participants

Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Elevated Lipoprotein(a)

Netherlands, United Kingdom, Denmark, Germany, Canada
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

New Zealand, United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers

Healthy Volunteers

Canada
Ionis Pharmaceuticals, Inc.

Completed

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients (FGFR4-CS2)

Obesity

United States

Clinical Trials Sponsored by Ionis Pharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations